Contact us

Thank you for your interest in Garg Law PLLC.

Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.

If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.

FDA Commits to Series of Actions Following Summer 2026 Cyclospora Outbreaks

Following multiple Cyclospora outbreaks this past summer, the U.S. Food and Drug Administration (FDA) is announcing ten planned activities to mitigate and prevent future Cyclospora outbreaks. The agency plans to carry out these activities between now and the beginning of the 2027 growing season. This announcement coincides with the conclusion of the agency’s multistate outbreak investigation of Cyclospora infections linked to iceberg lettuce and underscores that the FDA’s work to address Cyclospora is far from over.

The activities the FDA plans to conduct in advance of the 2027 growing and harvesting season are focused on surveillance, outreach, and finding innovative solutions to prevent Cyclospora contamination of fresh produce. As part of these activities, the FDA will publish an Outbreak Investigation Report that will summarize the multistate outbreak investigation and provide recommendations to help mitigate and prevent future outbreaks. The agency also will increase surveillance of commodities historically associated with Cyclospora, conduct additional outreach and public engagement to help growers adopt practices that reduce the risk of Cyclospora contamination, and update its Cyclospora Prevention, Response and Research Action Plan to lay the groundwork for stronger prevention and response in future growing seasons.

To view the full list of the ten activities the FDA plans to conduct to mitigate Cyclospora contamination of fresh produce before the 2027 growing season, visit the Cyclospora post-response activities page.

Request a Consultation

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.
R.G. Client
I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.
Mike H. Client
Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.
Dr. Sastry Client
I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.
Claire P. Client

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.